Discovery of novel P2Y14 agonist and antagonist using conventional and nonconventional methods.

P2Y14 is a member of the pyrimidinergic GPCR family. UDP-Glc has been previously shown to activate human P2Y14, whereas UDP was unable to activate the receptor. In this study, the authors used conventional and nonconventional methods to further characterize P2Y14 and its ligands. Conventional calcium mobilization and nonconventional cellular impedance functional assays revealed that UMP and UDP selectively activated HEK cells coexpressing P2Y14 and G alpha(qi5). In the impedance assays, the presence of exogenous G alpha(qi5) resulted in agonist-induced Gq signaling, whereas in the absence of exogenous G alpha(qi5), the signal was indicative of Gi. The authors established the first P2Y14 membrane filtration binding assay using a novel optimized expression vector and [H-3]UDP as radioligand. UDP-Glc, UMP, and UDP dose dependently inhibited [3H] UDP binding in the binding assay, and saturation analysis revealed that UDP bound P2Y14 with a K-D = 10 nM and a B-max = 110 pmol/mg. The authors screened a phosphonate library and identified compound A, which inhibited UDP-Glc-mediated calcium signaling in the fluorometric imaging plate reader assay (IC50 = 2.3 mu M) and competed for [H-3]UDP binding in the novel binding assay with a K-i = 1280 nM. (Journal of Biomolecular Screening 2011;16:1098-1105)